Search

Displaying results 4171 - 4180 of 7059 in total
  1. Drug

    Berotralstat

    go.drugbank.com/drugs/DB15982
    ApprovedInvestigational

    Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). … [L26661] Berotralstat was approved by the European Commission on April 30, 2021 [L41965] and by Health Canada on June 06, 2022.

  2. Drug

    Mitapivat

    go.drugbank.com/drugs/DB16236
    ApprovedInvestigational

    Mitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. … [A245478] On February 17, 2022, the FDA approved mitapivat as the first disease-modifying treatment for hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, inherited disorder leading

  3. Drug

    Nylidrin

    go.drugbank.com/drugs/DB06152
    ApprovedWithdrawn

    Nylidrin is a peripheral vasodilator. … Therefore, the FDA has withdrawn nylidrin from the U.S. market [L2286].

  4. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    [L64069] Oveporexton has been recommended for scheduling as a controlled substance, and its final controlled-substance schedule and commercial availability are pending a determination by the Drug Enforcement … [L64069] The FDA approved oveporexton on August 5, 2026 for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults.

  5. Drug

    5-methyltetrahydrofolic acid

    go.drugbank.com/drugs/DB04789
    InvestigationalNutraceutical

    5-methyltetrahydrofolic acid is a methylated derivate of tetrahydrofolate.

    Mixtures: FeRiva 21-7 28-DayInternational brands: Prefolic A
  6. Drug

    Ensifentrine

    go.drugbank.com/drugs/DB16157
    ApprovedInvestigational

    Ensifentrine is a first-in-class, selective dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes. … [L50903] On June 26, 2024, the FDA announced the approval of an inhaled product of ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD) in adults, which allows the drug to be

    Synonyms: 2-(9,10-DIMETHOXY-4-OXO-2-(2,4,6-TRIMETHYLPHENYL)IMINO-6,7-DIHYDROPYRIMIDO(6,1-A)ISOQUINOLIN-3-YL)ETHYLUREA, N-(2-((2E)-9,10-DIMETOXI-4-OXO-2-((2,4,6-TRIMETILFENIL)IMINO)-6,7-DIHIDRO-2H-PIRIMIDO(6,1-A)ISOQUINOLEIN-3(4H)-IL)ETIL)UREA
  7. Drug

    Etidronic acid

    go.drugbank.com/drugs/DB01077
    ApprovedInvestigational

    [A203111] Etidronic acid was granted FDA approval on 1 September 1977.[L13901] … Etidronic acid is a first generation bisphosphonate similar to [clodronic acid] and [tiludronic acid].

  8. Drug

    Bretylium

    go.drugbank.com/drugs/DB01158
    Approved

    Recent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site.

  9. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    Deutivacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. … [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive

    Synonyms: D9-Ivacaftor
  10. Drug

    Benzhydrocodone

    go.drugbank.com/drugs/DB15465
    Approved

    Benzhydrocodone is a benzylic prodrug of hydrocodone.[L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse. … It was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862]